Related Experiment Video
Updated: May 18, 2026

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
The protein tyrosine phosphatase receptor type J is regulated by the pVHL-HIF axis in clear cell renal cell carcinoma
Silvia Casagrande1, Melanie Ruf, Markus Rechsteiner
1Institute of Surgical Pathology, University Hospital Zurich, Schmelzbergstrasse 12, 8091, Zurich, Switzerland.
Abstract:
Mass spectrometry analysis of renal cancer cell lines recently suggested that the protein-tyrosine phosphatase receptor type J (PTPRJ), an important regulator of tyrosine kinase receptors, is tightly linked to the von Hippel-Lindau protein (pVHL). Therefore, we aimed to characterize the biological relevance of PTPRJ for clear cell renal cell carcinoma (ccRCC). In pVHL-negative ccRCC cell lines, both RNA and protein expression levels of PTPRJ were lower than those in the corresponding pVHL reconstituted cells. Quantitative RT-PCR and western blot analysis of ccRCC with known VHL mutation status and normal matched tissues as well as RNA in situ hybridization on a tissue microarray (TMA) confirmed a decrease of PTPRJ expression in more than 80% of ccRCCs, but in only 12% of papillary RCCs. ccRCC patients with no or reduced PTPRJ mRNA expression had a less favourable outcome than those with a normal expression status (p = 0.05). Sequence analysis of 32 PTPRJ mRNA-negative ccRCC samples showed five known polymorphisms but no mutations, implying other mechanisms leading to PTPRJ's down-regulation. Selective silencing of HIF-α by siRNA and reporter gene assays demonstrated that pVHL inactivation reduces PTPRJ expression through a HIF-dependent mechanism, which is mainly driven by HIF-2α stabilization. Our results suggest PTPRJ as a member of a pVHL-controlled pathway whose suppression by HIF is critical for ccRCC development.
Insights
The protein-tyrosine phosphatase receptor type J (PTPRJ) is downregulated in clear cell renal cell carcinoma (ccRCC) due to VHL inactivation. This suppression, mediated by HIF-2α, is critical for ccRCC development.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The von Hippel-Lindau (VHL) protein (pVHL) is a key tumor suppressor.
- pVHL inactivation is common in clear cell renal cell carcinoma (ccRCC).
- PTPRJ, a regulator of tyrosine kinase receptors, was recently linked to pVHL.
Purpose of the Study:
- To investigate the biological role of PTPRJ in ccRCC.
- To determine the relationship between PTPRJ expression and VHL status in ccRCC.
- To elucidate the mechanism of PTPRJ regulation in ccRCC.
Main Methods:
- Quantitative RT-PCR and Western blot analysis.
- RNA in situ hybridization on tissue microarrays (TMAs).
- siRNA-mediated gene silencing and reporter gene assays.
Main Results:
- PTPRJ expression was significantly decreased in ccRCC compared to normal tissues and papillary RCC.
- Reduced PTPRJ mRNA expression correlated with a less favorable outcome in ccRCC patients.
- pVHL inactivation led to decreased PTPRJ expression via a HIF-dependent mechanism, primarily involving HIF-2α stabilization.
Conclusions:
- PTPRJ is a tumor suppressor in ccRCC, acting downstream of pVHL.
- HIF-mediated suppression of PTPRJ is a critical event in ccRCC pathogenesis.
- PTPRJ represents a potential therapeutic target in ccRCC.
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Receptor Tyrosine Kinases
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
The JAK-STAT Signaling Pathway
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
